F. Tranquart 1, B. Petit 1,2, E. Bihel 1, Y. Bohren 1, F. Yan 1, E. Allemann 2, M. Arditi 1, J. M. Hyvelin 1
1 BRACCO SUISSE SA – Plan Les Ouates, Switzerland, 
2 School of Pharmaceutical Sciences, University of Geneva, University of Lausanne – Geneva, Switzerland

Rapid restoration of vascular flow is the primary goal of acute stroke treatment, while improvement in patient’s outcome is the ultimate benefit of such treatments. Among different treatment schemes, sonothrombolysis has been used in in vitro tests, in preclinical trials and to a lesser extent in clinical trials, even though the exact underlying mechanism has not been fully clarified.

J. Powers 1, R. Seip 2, W. Shi 2
1 Philips Ultrasound, Bothell – WA, USA, 
2 Philips Research, Briarcliff – NY, USA

For many years existing ultrasound devices have been used for sonothrombolysis (STL) research in-vitro, in animals, and even in humans. These have included laboratory transducers, physiotherapy devices, and diagnostic ultrasound systems.

J. Shimizu 1, J. Kubota 1, T. Fukuda 2, A. Sasaki 3, T. Azuma 3, K. Sasaki 4, K. Shimizu 5, T. Oishi 6, S. Umemura 7, H. Furuhata 1
1 Medical Engineering Laboratory,
2 Division of Neuropathology, The Jikei University School of Medicine – Tokyo, Japan
3 Faculty of Engineering, The University of Tokyo – Tokyo, Japan
4 Department of Veterinary Medicine, Tokyo University of Agriculture and Technology – Tokyo, Japan
5 Department of Zoology, Faculty of Science, Okayama University of Science – Okayama, Japan
6 Department of Cellular and Molecular Biology, Primate Research Institute, Kyoto University – Inuyama, Japan
7 Graduate School of Biomedical Engineering, Tohoku University – Sendai, Japan

Objective: We are developing mid-frequency sonothrombolysis, however, hemorrhagic complication in TRUMBI trial is a fence at these frequency. We evaluated safety in primate with a developed 490 kHz continuous waveform (CW)-US probe and investigated 400 kHz burst waveform (BW)-US emission for rabbit.